| Authors: |
Willett C; Humane World for Animals, USA; Cefic, Belgium. Electronic address: kwillett@humaneworld.org., Pallocca G; Humane World for Animals, USA. Electronic address: gpallocca@humaneworld.org., Carusi A; Interchange Research, UK. Electronic address: a.carusi@inter-changeresearch.com., Alépée N; L'Oreal, France. Electronic address: nathalie.alepee@loreal.com., Browne P; Organization for Economic Cooperation and Development, UK. Electronic address: Patience.BROWNE@oecd.org., Darracq-Ghitalla-Ciock M; KREATiS, France. Electronic address: marie.darracq@kreatis.eu., Grimm FA; Clariant Produkte (Deutschland) GmbH, Germany. Electronic address: fabian.grimm@clariant.com., Ingram J; Humane World for Animals, USA. Electronic address: jingram@humaneworld.org., Holden L; University of Birmingham, UK. Electronic address: l.holden.1@bham.ac.uk., Mansouri K; NICEATM, USA. Electronic address: kamel.mansouri@nih.gov., Raabe H; Institute for In Vitro Sciences, USA. Electronic address: hraabe@iivs.org., Roper C; Roper Toxicology Consulting Limited, UK. Electronic address: Clive@RoperTCL.com., Santizo K; Cefic, Belgium. Electronic address: kas@cefic.be., Schmitt BG; Evonik Operations GmbH, Germany. Electronic address: barbara1.schmitt@evonik.com., Xiang L; CIRS, Ireland. Electronic address: li.xiang@cirs-reach.com., Ward TA; XCellR8, UK. Electronic address: tom.ward@x-cellr8.com., Zhou B; CIRS, Ireland. Electronic address: bryan.zhou@cirs-group.com. |
